Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia

Bronx VA Medical Center30 enrolled

Overview

Recently, research studies have shown that patients who have had trouble taking statins every day, are able to take statins if they take them only once or twice a week. The investigators are doing a research study which involves switching people who are taking ezetimibe to the statin Crestor once or twice a week and to see how ell Crestor lowers cholesterol and if it is tolerated.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Enrollment

Conditions

Hypercholesterolemia

Interventions

RosuvastatinDRUG

Rosuvastatin 10 or 20 milligrams once or twice a week

EzetimibeDRUG

Ezetimibe 5 or 10 milligrams

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with a history of intolerance to statins * Patients currently receiving ezetimibe * Patients willing and able to provide signed informed consent Exclusion Criteria: * Patients receiving a statin (Lipitor, Crestor, Lescol, Simvastatin, or Pravachol) * Stroke, TIA, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass surgery, or major surgery within 3 months * Cancer undergoing active treatment * Creatinine clearance \< 40 ml/minute * Active liver disease or persistent elevation of SGOT or SGPT \> 2 times the upper limit of normal level * Participation in any clinical study within the last 30 days * Drug addition or alcohol abuse within the past 6 months * Use of cyclosporine within the last 3 months * Use of gemfibrozil within the last month * Patients unwilling or unable to provide informed consent * Patients with poor compliance * Women of childbearing potential * History of rhabdomyolysis due to statins

Locations (1)

Bronx VA Medical Center

The Bronx, New York, United States

RECRUITING

Outcomes

Primary Outcomes

Low-density lipoprotein (LDL) cholesterol

Time frame: 6 weeks

Low-density lipoprotein (LDL) cholesterol

Time frame: 3-4 months

Secondary Outcomes

The ability to remain on Crestor for the study period

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.